Date: 2011-07-25
Type of information: R&D agreement
Compound:
Company: AbD Serotec unit - MorphoSys AG (Germany) Dana-Farber Cancer Institute (USA)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: AbD Serotec unit - MorphoSys AG (Germany) has entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.
Financial terms:
Latest news:
